Corporate debt recently passed the $1 trillion mark in a continuing sign of global financial displacement.Marketsread more
"Federal debt, which is already high by historical standards, is on an unsustainable course," CBO director Phillip Swagel said in the report.Politicsread more
Target CEO Brian Cornell still thinks the U.S. consumer is strong and spending. Target's latest quarterly results showed the big-box retailer is benefiting from that.Retailread more
"If you look at the market over the past week, stocks don't need any help. They are roaring ahead, without the Fed doing anything," says the longtime market strategist.Marketsread more
Stocks rose on Wednesday as strong quarterly results from retailers such as Target and Lowe's lifted investor sentiment.US Marketsread more
President Trump insists the economy is healthy and says the only thing holding U.S. growth back is the Federal Reserve.Marketsread more
Trading volumes this week are well below recent averages, and that means this comeback may be suspect.Marketsread more
Shares of Tesla slid Wednesday on news of Walmart's lawsuit.Technologyread more
The rule could defy a 2015 Flores Settlement Agreement court order that says families cannot be held in detention for more than 20 days.Politicsread more
A key indicator for the commercial real estate market is showing signs of weakness, and uncertainty in the economy over the trade war and interest rates may be to blame.Real Estateread more
Bank of America CEO Brian Moynihan is not worried about an economic slowdown, saying the U.S. consumer is still in a strong place.Banksread more
* Oncology, rare diseases, neuroscience to remain key areas
* Has more than 300 million euros for potential deals
* 2022 sales seen topping 3 billion euros
PARIS, May 14 (Reuters) - French drugmaker Ipsen is hunting for deals to add to its pipeline of experimental medicines both this year and beyond, its chief executive told Reuters.
The 90-year-old company, which holds an investor day on Tuesday, is targetting sales of around 3.2 billion euros ($3.6 billion) in 2022 and an operating margin above 32 percent.
That compares with 2018 revenue of 2.22 billion euros, which was up more than 20 percent from 2017 at constant exchange rates, and an operating margin just shy of 30 percent.
"We are going to continue our external innovation strategy. We are very aggressive today as we want to bring in new assets to the organisation," David Meek told Reuters in an interview.
Under Meek, an American who took over as CEO in July 2016, Ipsen has become more international, with an increased focus on the United States, the world's biggest and most profitable drugs market.
The company has been looking to strengthen its portfolio to offset the long-term generic threat to its top-selling cancer treatment Somatuline.
Ipsen currently has five new chemical entities in clinical development and nine "significant" regulatory submissions planned for 2019-2022, Meek said.
Earlier this year, Ipsen agreed to buy Canadian biotech firm Clementia Pharmaceuticals in a deal worth up to $1.31 billion.
Clementia has a key product called palovarotene that treats bone disorders, and it hopes to get regulatory approval from the U.S. Food and Drug Administration for the medicine in 2020.
"We have the financial firepower to do more transactions this year," Meek said, citing oncology, rare diseases and neuroscience as the core therapeutic areas where the group remains keen to expand.
Although valuations in oncology have been high for some time, Meek said the group's size allowed it to look at drugs with peak annual sales potential of a few hundred million dollars that are not considered by bigger pharmaceutical firms.
Ipsen has more than 300 million euros for potential deals and that warchest is expected to top 1 billion euros by the end of 2020.
"It could be full-on asset acquisitions, licensing deals, partnerships, we can be opportunistic and we are open to the source of innovation," Meek said.
So far, the company has opted for a series of mid-sized deals rather than multibillion dollars transactions that attract greater scrutiny from investors and regulators.
In addition to a team of 30 that is searching for targets, Ipsen has teamed up with venture capital partners to help it source new assets.
"We have multiplied the number of eyes and ears," Meek said.
($1 = 0.8904 euros) (Reporting by Matthias Blamont; Editing by Mark Potter)